Table 3 Number of observed second primary cancers (Obs) following breast cancer, diagnosed between 1958 and 2000, standardised incidence ratios (SIRs), and 95% confidence interval (CI) for second primary malignancy according to family history of breast cancer

From: Family history of breast cancer and young age at diagnosis of breast cancer increase risk of second primary malignancies in women: a population-based cohort study

 

Family history of breast cancer

 
 

Yes

No

 

Second primary cancer site

Obs

SIR

95% CI

Obs

SIR

95% CI

Ratio

Oesophagus

7

3.76

(1.49–7.07)

58

1.69

(1.29–2.16)

2.22*

Stomach

27

2.65

(1.74–3.74)

296

1.41

(1.26–1.58)

1.88*

Colorectum

46

1.10

(0.81–1.45)

1010

1.18

(1.11–1.25)

0.93

Pancreas

9

0.86

(0.39–1.52)

253

1.18

(1.04–1.33)

0.73

Lung

16

0.91

(0.52–1.41)

483

1.45

(1.32–1.58)

0.63

Endometrium

41

1.94

(1.39–2.58)

589

1.45

(1.34–1.57)

1.33

Ovary

40

2.32

(1.66–3.10)

437

1.38

(1.25–1.51)

1.68*

Kidney

8

0.89

(0.38–1.61)

239

1.29

(1.14–1.46)

0.69

Melanoma

18

1.67

(1.00–2.53)

231

1.28

(1.12–1.45)

1.31

Nervous system

13

1.20

(0.63–1.94)

236

1.25

(1.09–1.41)

0.96

Thyroid

5

1.51

(0.48–3.12)

104

1.78

(1.46–2.14)

0.85

Endocrine glands

12

1.37

(0.70–2.25)

199

1.19

(1.03–1.36)

1.15

Connective tissue

5

2.48

(0.78–5.12)

79

2.06

(1.63–2.54)

1.20

Non-Hodgkin's lymphoma

23

2.41

(1.52–3.49)

231

1.13

(0.99–1.28)

2.13*

Leukaemia

19

2.25

(1.35–3.38)

218

1.29

(1.13–1.47)

1.74*

All the above sites

289

1.58

(1.40–1.77)

4663

1.31

(1.27–1.35)

1.21*

  1. Standardised incidence ratio for women with family history of breast cancer was compared with SIR for women without family history of breast cancer (ratio).
  2. Bold denotes statistical significance; * denotes statistically significant ratio.